Initial results of a clinical trial of Fluosol-DA 20 percent in acute cerebral ischemia.

We present three patients in whom Fluosol-DA 20 percent was administered in the presence of ischemic cerebral vascular disease. While transient improvement observed in two cases may have been related to Fluosol-DA administration it is premature to use these results to comment on the potential protective or therapeutic efficacy of Fluosol-DA in ischemic cerebral vascular disease. One patient progressively deteriorated neurologically during and after the infusion. Our initial impressions are limited to the observations that Fluosol-DA in doses of 20 ml/kg can be administered easily and without major effects on hemodynamic or pulmonary function. One patient had a transient leukopenia.